Sheffield Medical Technologies Inc., Baylor College of Medicine deal

SHM exercised its option to obtain an exclusive license to Baylor's UGIF technology to inhibit DNA synthesis and proliferation of human prostatic carcinoma cells. SHM's license includes ps20, the protein responsible for the activity of UGIF. The technology is in preclinical studies.

Separately, SHM's Ion Pharmaceuticals Inc. subsidiary agreed with the Children's Hospital of Boston to develop Trifens, a group of anti-proliferative compounds to treat diarrhea and other gastrointestinal diseases. ...